<DOC>
	<DOCNO>NCT02206204</DOCNO>
	<brief_summary>This single-center , double-blind , randomize , placebo- positive-controlled , double-dummy , parallel-group , multiple-dose , up-titration study nest cross-over comparison moxifloxacin placebo healthy male female subject . The primary objective demonstrate selexipag metabolite ACT-333679 effect cardiac repolarization exceed threshold regulatory concern , two orally administer dose level ( 800 1600 μg twice daily ) healthy male female subject . Moxifloxacin include positive control .</brief_summary>
	<brief_title>Study Selexipag Its Metabolite ACT-333679 Cardiac Repolarization Healthy Male Female Subjects</brief_title>
	<detailed_description />
	<mesh_term>Selexipag</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Signed , date write informed consent prior study procedure . Ability communicate well investigator local language , understand comply requirement study . Women childbearing potential must negative serum pregnancy test screen negative serum pregnancy test Day −1 . Women childbearing potential must consistently correctly use reliable method contraception failure rate &lt; 1 % per year , sexually inactive , vasectomized partner . Healthy base medical history assessment perform screen Day −1 . Body mass index ≥ 18.5 ≤ 32 kg/m^2 screening . Body weight least 50 kg . Negative result urine drug screen screen Day −1 negative urine alcohol test Day −1 . Willing refrain alcohol consumption least 48 hour prior clinic admission end study . Systolic blood pressure 90145 mmHg , diastolic blood pressure 5090 mmHg , pulse rate 4590 beat per minute , screen Day −1 . Hematology , blood chemistry , urinalysis result deviate normal range clinically relevant extent screen Day −1 . Known hypersensitivity selexipag , moxifloxacin , excipients drug formulation use study . Treatment selexipag investigational drug prior screen within 30 day 6 halflives , whichever longer . History clinical evidence disease and/or existence surgical medical condition , might interfere absorption , distribution , metabolism , excretion selexipag moxifloxacin . Caffeine consumption equal great 800 mg per day screening . History fainting , collapse , syncope , blackout , orthostatic hypotension , vasovagal reaction . Chronic relevant acute infection . History relevant allergy / hypersensitivity . History clinical evidence psychiatric disease , alcoholism , drug abuse within 3year period prior screen . Smoking within 3 month prior screen inability refrain smoking study . Loss 500 mL blood within 56 day prior screen . Positive result hepatitis serology , except vaccinated subject screen . Positive result human immunodeficiency virus serology screen . Previous treatment prescribe overthecounter medication , exception contraceptive hormone replacement therapy , within 2 week prior first study drug administration 5 halflives , whichever longer . Excessive physical activity within 1 week prior administration study drug . Any cardiac condition ( include ECG abnormality ) illness potential increase cardiac risk subject may affect QTc analysis . QTc &gt; 450 m &gt; 470 m male female subject , respectively , screen Day −1 . Clinically relevant abnormality ECG , screen Day −1 . Personal family history long QT syndrome hypokalemia . Legal incapacity limit legal capacity . Veins unsuitable intravenous puncture either arm . Any circumstance condition , , opinion investigator , may affect subject 's participation study compliance protocol . Pregnant nursing woman . Women plan become pregnant within 1 month end study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Selexipag</keyword>
	<keyword>ACT-333679</keyword>
</DOC>